ATI-450 (zunsemetinib)
Rheumatoid Arthritis
Key Facts
About Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies for immuno-inflammatory diseases with high unmet need. The company's core strength is its proprietary KINect® platform, which enables rapid discovery of selective kinase inhibitors. Having divested its commercial assets, Aclaris now focuses entirely on advancing a promising pipeline, including candidates for rheumatoid arthritis, alopecia areata, and atopic dermatitis, aiming to address critical 'white spaces' in treatment paradigms.
View full company profileAbout Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies for immuno-inflammatory diseases with high unmet need. The company's core strength is its proprietary KINect® platform, which enables rapid discovery of selective kinase inhibitors. Having divested its commercial assets, Aclaris now focuses entirely on advancing a promising pipeline, including candidates for rheumatoid arthritis, alopecia areata, and atopic dermatitis, aiming to address critical 'white spaces' in treatment paradigms.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |
| AX-158 | Artax Biopharma | Phase 2 |